KRAS mutations drive tumor survival, growth, and immune escape in colorectal, non-small cell lung, and pancreatic ductal adenocarcinomas by reprogramming cancer cell metabolism and reshaping metabolic interactions within the tumor microenvironment (141). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.